Editing Hypertriglyceridemia (section)

==Treatment==
Lifestyle changes including weight loss, exercise and dietary modification may improve hypertriglyceridemia.<ref>{{Cite journal | vauthors = Koneru SC |date=2022-03-01 |title=Fellow's voice: Hypertriglyceridemia: Understanding the current guideline  |journal=American Journal of Preventive Cardiology |language=en |volume=9 |pages=100322 |doi=10.1016/j.ajpc.2022.100322 |pmid=35243465 |issn=2666-6677 |pmc=8885448}}</ref><ref name=CPG2012/><ref name="Nordestgaard2014">{{cite journal | vauthors = Nordestgaard BG, Varbo A | title = Triglycerides and cardiovascular disease | journal = Lancet | volume = 384 | issue = 9943 | pages = 626–635 | date = August 2014 | pmid = 25131982 | doi = 10.1016/S0140-6736(14)61177-6 | s2cid = 33149001 }}</ref><ref>{{cite journal | vauthors = Gill JM, Herd SL, Tsetsonis NV, Hardman AE | title = Are the reductions in triacylglycerol and insulin levels after exercise related? | journal = Clinical Science | volume = 102 | issue = 2 | pages = 223–231 | date = February 2002 | pmid = 11834142 | doi = 10.1042/cs20010204 }}</ref> This may include dietary changes such as restriction of fat and carbohydrates (specifically [[fructose]]<ref name="Nordestgaard2014"/><ref>{{Cite journal |last=European Association for Cardiovascular Prevention & Rehabilitation |last2=Reiner |first2=Zeljko |last3=Catapano |first3=Alberico L. |last4=De Backer |first4=Guy |last5=Graham |first5=Ian |last6=Taskinen |first6=Marja-Riitta |last7=Wiklund |first7=Olov |last8=Agewall |first8=Stefan |last9=Alegria |first9=Eduardo |last10=Chapman |first10=M. John |last11=Durrington |first11=Paul |last12=Erdine |first12=Serap |last13=Halcox |first13=Julian |last14=Hobbs |first14=Richard |last15=Kjekshus |first15=John |date=July 2011 |title=ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) |url=https://pubmed.ncbi.nlm.nih.gov/21712404/ |journal=European Heart Journal |volume=32 |issue=14 |pages=1769–1818 |doi=10.1093/eurheartj/ehr158 |issn=1522-9645 |pmid=21712404}}</ref> and [[sugar-sweetened beverages]]<ref name="CPG2012"/>) and increased consumption of [[omega-3 fatty acid]]s from algae, nuts, and seeds.<ref name="TheLipid2008">{{cite book | vauthors = Davidson MH, Cannon CP, Armani AM | veditors = Davidson MH, Toth PP, Maki KC |title= Therapeutic Lipidology  |url=https://archive.org/details/therapeuticlipid00davi |url-access=limited |chapter = Pharmacological Therapy for Cardiovascular Disease |pages= [https://archive.org/details/therapeuticlipid00davi/page/n155 141]–142 |series  = Contemporary Cardiology|date= 28 January 2008 |publisher=Humana Press, Inc. |location  = Totowa, New Jersey|isbn = 978-1-58829-551-4}}</ref><ref>{{cite journal | vauthors = Anagnostis P, Paschou SA, Goulis DG, Athyros VG, Karagiannis A | title = Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit? | journal = Maturitas | volume = 108 | pages = 45–52 | date = February 2018 | pmid = 29290214 | doi = 10.1016/j.maturitas.2017.11.011 | doi-access = free }}</ref>

The decision to treat hypertriglyceridemia with medication depends on the levels and on the presence of other risk factors for cardiovascular disease. Very high levels that would increase the risk of pancreatitis is treated with a drug from the [[fibrate]] class. [[Niacin (substance)|Niacin]] and [[omega-3 fatty acid]]s as well as drugs from the [[statin]] class may be used in conjunction, with statins being the main drug treatment for moderate hypertriglyceridemia where reduction of cardiovascular risk is required.<ref name=CPG2012/> Medications are recommended in those with high levels of triglycerides that are not corrected with lifestyle modifications, with [[fibrate]]s being recommended first.<ref name=CPG2012/><ref>{{cite journal | vauthors = Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ | display-authors = 6 | title = Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review | journal = The American Journal of Medicine | volume = 122 | issue = 10 | pages = 962.e1–962.e8 | date = October 2009 | pmid = 19698935 | doi = 10.1016/j.amjmed.2009.03.030 }}</ref><ref>{{cite journal | vauthors = Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V | display-authors = 6 | title = Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis | journal = Lancet | volume = 375 | issue = 9729 | pages = 1875–1884 | date = May 2010 | pmid = 20462635 | doi = 10.1016/S0140-6736(10)60656-3 | s2cid = 15570639 }}</ref> [[Epanova (omega-3-carboxylic acids)]] is another prescription drug used to treat very high levels of blood triglycerides.<ref>{{cite journal | vauthors = Blair HA, Dhillon S | title = Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia | journal = American Journal of Cardiovascular Drugs | volume = 14 | issue = 5 | pages = 393–400 | date = October 2014 | pmid = 25234378 | doi = 10.1007/s40256-014-0090-3 | s2cid = 23706094 }}</ref>